2. Search Result
Search Result
Results for "

GCPII

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

14

Recombinant Proteins

4

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100788
    2-PMPA
    5 Publications Verification

    2-(Phosphonomethyl)pentanedioic acid

    		 Carboxypeptidase Neurological Disease
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA is applicable to the research of neurological diseases .
    2-PMPA
  • HY-W096171
    D-Dopa

    3-Hydroxy-D-tyrosine

    		 Carboxypeptidase Infection Neurological Disease
    D-Dopa (3-Hydroxy-D-tyrosine) is a potent, orally active, non-competitive and allosteric inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 200 nM. D-Dopa elevates brain dopamine and produce turning behavior in rats. D-Dopa inhibit severe fever with thrombocytopenia syndrome (SFTS) virus infection. D-Dopa can be used for neurological disease and virus infection research .
    D-Dopa
  • HY-139840
    GCPII-IN-1

    		PSMA Carboxypeptidase Cancer
    GCPII-IN-1 (Compound 2) is a GCPII (also known as PSMA) inhibitor with a Ki of 44.3 nM. GCPII-IN-1 can be used in the research of prostate cancer .
    GCPII-IN-1
  • HY-139840A
    GCPII-IN-1 TFA

    		PSMA Carboxypeptidase Cancer
    GCPII-IN-1 (Compound 2) TFA is a GCPII (also known as PSMA) inhibitor with a Ki of 44.3 nM. GCPII-IN-1 TFA can be used in the research of prostate cancer .
    GCPII-IN-1 TFA
  • HY-100788C
    2-PMPA sodium
    5 Publications Verification

    2-(Phosphonomethyl)pentanedioic acid sodium

    		 Carboxypeptidase Neurological Disease
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) sodium is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA sodium shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA sodium is applicable to the research of neurological diseases .
    2-PMPA sodium
  • HY-100788R
    2-PMPA (Standard)

    2-(Phosphonomethyl)pentanedioic acid (Standard)

    		 Reference Standards Carboxypeptidase Neurological Disease
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) Standard is the analytical standard of 2-PMPA (HY-100788). This product is intended for research and analytical applications. 2-PMPA (2-(Phosphonomethyl)pentanedioic acid) sodium is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA sodium shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA sodium is applicable to the research of neurological diseases.
    2-PMPA (Standard)
  • HY-RS05028
    FOLH1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FOLH1 Human Pre-designed siRNA Set A contains three designed siRNAs for FOLH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FOLH1 Human Pre-designed siRNA Set A
    FOLH1 Human Pre-designed siRNA Set A
  • HY-165571
    E2072

    		Carboxypeptidase Neurological Disease
    E2072 is a selective, orally active competitive inhibitor of glutamate carboxypeptidase II (GCPII) with a Ki of 10 nM. E2072 alleviates established thermal hyperalgesia in a rat model of chronic constriction injury. E2072 prevents oxaliplatin-induced reductions in nerve conduction velocity and amplitude in mice. E2072 is applicable to research related to neuropathic pain and neuropathy .
    E2072
  • HY-D3353
    PSMA-SulfoCy7

    		PSMA Cancer
    PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a Ki of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies .
    PSMA-SulfoCy7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: